Начало › Рак на белия дроб с недребноклетъчен тип › Вирджиния › Arlington
Клинични проучвания за Рак на белия дроб с недребноклетъчен тип в Arlington, VA
104 проучвания за Рак на белия дроб с недребноклетъчен тип търсят участници в обекти в и около Arlington (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Набиране на участнициФаза 3
- Kaiser Permanente Tysons Corner Medical Center, McLean · на 5 мили
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Набиране на участнициФаза 3
- Virginia Cancer Specialists ( Site 0167), Fairfax · на 11 мили
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Набиране на участнициФаза 1/2
- Virginia Cancer Specialists, Fairfax · на 11 мили
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Набиране на участнициФаза 2/3
- Virginia Cancer Specialists, PC, Fairfax · на 11 мили
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1
- Inova Schar Cancer Institute, Fairfax · на 11 мили
- NEXT Virginia, Fairfax · на 11 мили
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Набиране на участнициФаза 3
- Virginia Cancer Specialists ( Site 0114), Fairfax · на 11 мили
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Набиране на участнициФаза 1
- ALX Center 2, Fairfax · на 11 мили
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
Набиране на участнициФаза 1
- Site 04, Fairfax · на 11 мили
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Набиране на участнициФаза 2
- Virginia Cancer Specialists, Fairfax · на 11 мили
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Набиране на участнициФаза 3
- Virginia Cancer Specialists, Fairfax · на 11 мили
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Набиране на участнициФаза 3
- Virginia Cancer Specialists, Fairfax · на 11 мили
A Study of PHN-012 in Patients With Advanced Solid Tumors
Набиране на участнициФаза 1
- PHN-012-001 Site, Fairfax · на 11 мили
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Набиране на участнициФаза 2
- Virginia Cancer Specialists, Fairfax · на 11 мили
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
Набиране на участнициФаза 1/2
- Virginia Cancer Specialists, Fairfax · на 11 мили
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 2
- Virginia Cancer Specialists, Fairfax · на 11 мили
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 1
- Virginia Cancer Specialists PC, Fairfax · на 11 мили
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Набиране на участнициФаза 2
- Research Site, Fairfax · на 11 мили
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Набиране на участнициФаза 2/3
- Virginia Cancer Specialists - Arlington, Arlington
- Virginia Cancer Specialists, Fairfax · на 11 мили
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Набиране на участнициФаза 1/2
- NEXT Oncology Virginia, Fairfax · на 11 мили
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 2
- Virginia Cancer Specialists - Fairfax /ID# 272004, Fairfax · на 11 мили
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Набиране на участнициФаза 1/2
- Inova Schar Cancer Institute Clinical Trials, Fairfax · на 11 мили
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Набиране на участнициФаза 1
- Virginia Cancer Specialists, Fairfax · на 11 мили
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Набиране на участнициФаза 1/2
- Next Oncology Virginia Cancer Specialist, Fairfax · на 11 мили
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 3
- Research Site, Fairfax · на 11 мили
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Набиране на участнициФаза 3
- Clinical Study Site, Fairfax · на 11 мили
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Набиране на участнициФаза 3
- Virginia Cancer Specialists, Arlington
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Набиране на участнициФаза 1
- NEXT - Virginia, Fairfax · на 11 мили
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Набиране на участнициФаза 3
- Virginia Cancer Specialists, PC, Fairfax · на 11 мили
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Набиране на участнициФаза 1/2
- NEXT Virginia, Fairfax · на 11 мили
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Набиране на участнициФаза 2/3
- Local Institution - 007-814-D, Arlington
- USOR - Virginia Cancer Specialists - Fairfax Office, Fairfax · на 11 мили
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Набиране на участнициФаза 1/2
- Virginia Cancer Specialists, Fairfax · на 11 мили
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Набиране на участнициФаза 1/2
- Inova Schar Cancer Institute, Fairfax · на 11 мили
- Next Oncology Virginia, Fairfax · на 11 мили
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 2
- Virginia Cancer Specialists (Fairfax) - USOR, Fairfax · на 11 мили
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Набиране на участнициФаза 1
- NEXT Oncology - Virginia Cancer Specialists, Fairfax · на 11 мили
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Набиране на участнициФаза 3
- USO - Virginia Cancer Specialists, Fairfax · на 11 мили
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1
- USO-Virginia Cancer Specialists, PC, Fairfax · на 11 мили
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Набиране на участнициФаза 1
- NEXT Oncology Virginia, Fairfax · на 11 мили
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Набиране на участнициФаза 3
- Research Site, Fairfax · на 11 мили
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Набиране на участнициФаза 1
- NEXT Oncology, Fairfax · на 11 мили
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
Набиране на участнициФаза 1/2
- NEXT Virginia, Fairfax · на 11 мили
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Набиране на участнициФаза 1/2
- NEXT Virginia, Fairfax · на 11 мили
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Набиране на участнициФаза 1
- Virginia Cancer Specialists, PC, Fairfax · на 11 мили
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Набиране на участнициФаза 1
- Virginia Cancer Specialists, Fairfax · на 11 мили
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1
- NEXT Virginia, Fairfax · на 11 мили
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Набиране на участнициФаза 3
- Virginia Cancer Specialists, Fairfax · на 11 мили
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Набиране на участнициФаза 2
- Virginia Cancer Specialists, Fairfax · на 11 мили
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Набиране на участнициФаза 3
- Research Site, Fairfax · на 11 мили
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Набиране на участнициФаза 1/2
- Virginia Cancer Specialists, Fairfax · на 11 мили
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Набиране на участнициФаза 1
- Inova Schar Cancer Institute, Falls Church · на 4 мили
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1/2
- Research Site, Fairfax · на 11 мили
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Набиране на участнициФаза 3
- Inova Schar Cancer Institute, Fairfax · на 11 мили
- Inova Fair Oaks Hospital, Fairfax · на 11 мили
A Study of DM005 in Patients With Advanced Solid Tumors
Набиране на участнициФаза 1/2
- NEXT Oncology Virginia, Fairfax · на 11 мили
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Набиране на участнициФаза 1/2
- Clinical Trial Site, Fairfax · на 11 мили
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Набиране на участнициФаза 1/2
- NEXT Virginia, Fairfax · на 11 мили
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 1/2
- NEXT Virginia, Fairfax · на 11 мили
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Набиране на участнициФаза 1
- NEXT Oncology - Virginia Cancer Specialists, Fairfax · на 11 мили
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Набиране на участнициФаза 1/2
- USOR Virginia Cancer Specialists, Fairfax · на 11 мили
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Набиране на участнициФаза 1/2
- NEXT Virginia, Fairfax · на 11 мили
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1
- Next Virginia, Fairfax · на 11 мили
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
Набиране на участнициФаза 3
- Virginia Cancer Specialists, Fairfax · на 11 мили
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Набиране на участнициФаза 1
- NEXT Virginia, Fairfax · на 11 мили
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Набиране на участнициФаза 1
- NEXT Virginia, Fairfax · на 11 мили
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Набиране на участнициФаза 1/2
- NEXT Virginia, Fairfax · на 11 мили
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Набиране на участнициФаза 1
- NEXT Virginia, Fairfax · на 11 мили
A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer
Набиране на участнициФаза 1/2
- Research Site, Fairfax · на 11 мили
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Набиране на участнициФаза 1
- Virginia Cancer Specialists, Fairfax · на 11 мили
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
Набиране на участнициФаза 1
- NEXT Virginia, Fairfax · на 11 мили
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 2
- Research Site, Fairfax · на 11 мили
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Набиране на участнициФаза 1/2
- NEXT Oncology Virginia, Fairfax · на 11 мили
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Набиране на участнициФаза 1
- Virginia Cancer Specialists - Fairfax /ID# 232592, Fairfax · на 11 мили
A Study of LY4175408 in Participants With Advanced Cancer
Набиране на участнициФаза 1
- NEXT Virginia, Fairfax · на 11 мили
Study of XB010 in Subjects With Solid Tumors
Набиране на участнициФаза 1
- Inova Schar Cancer, Fairfax · на 11 мили
- NEXT Virginia, Fairfax · на 11 мили
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Набиране на участнициФаза 1
- NEXT Texas LLC - Virginia, Fairfax · на 11 мили
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
Набиране на участнициФаза 1
- NEXT Virginia, Fairfax · на 11 мили
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1
- Research Site, Fairfax · на 11 мили
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Набиране на участнициФаза 1
- Research Site, Fairfax · на 11 мили
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Набиране на участнициФаза 2
- Kaiser Permanente Tysons Corner Medical Center, McLean · на 5 мили
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Набиране на участнициФаза 1
- NEXT Oncology Virginia, Fairfax · на 11 мили
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Набиране на участнициФаза 1/2
- NEXT Virginia, Fairfax · на 11 мили
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Набиране на участнициФаза 1/2
- NEXT Oncology, Fairfax · на 11 мили
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Набиране на участнициФаза 3
- Virginia Cancer Specialists, Fairfax · на 11 мили
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Набиране на участнициФаза 1
- NEXT Oncology Virginia, Fairfax · на 11 мили
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Набиране на участнициФаза 1/2
- Next Oncology Virginia, Fairfax · на 11 мили
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Набиране на участнициФаза 3
- Research Site, Fairfax · на 11 мили
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Набиране на участнициФаза 2
- Kaiser Permanente Tysons Corner Medical Center, McLean · на 5 мили
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Набиране на участнициФаза 2/3
- Kaiser Permanente Tysons Corner Medical Center, McLean · на 5 мили
A 2-part Phase 1/2 Open-label Trial on ODM-212
Набиране на участнициФаза 1/2
- NEXT Oncology Virginia, Fairfax · на 11 мили
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Набиране на участнициФаза 2
- Inova Fairfax Hospital, Fairfax · на 11 мили
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Набиране на участнициФаза 1/2
- NEXT Virginia, Fairfax · на 11 мили
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Набиране на участнициФаза 1/2
- Virginia Cancer Specialists, Fairfax · на 11 мили
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Набиране на участнициФаза 1
- Research Site, Fairfax · на 11 мили
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Набиране на участнициФаза 1/2
- NEXT Virginia, Fairfax · на 11 мили
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Набиране на участнициФаза 1/2
- NEXT Virginia, Fairfax · на 11 мили
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1
- NEXT Virginia, Fairfax · на 11 мили
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Набиране на участнициФаза 1/2
- Virginia Cancer Specialists, Fairfax · на 11 мили
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1/2
- NEXT Virginia, Fairfax · на 11 мили
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Набиране на участнициФаза 1/2
- NEXT, Virginia, Fairfax · на 11 мили
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Набиране на участнициФаза 1
- Dren Investigational Site, Fairfax · на 11 мили
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Набиране на участнициФаза 1
- Virginia Cancer Specialists, Fairfax · на 11 мили
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
Набиране на участнициФаза 1
- NEXT Oncology, Fairfax · на 11 мили
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Набиране на участнициФаза 1/2
- Research Site 102, Fairfax · на 11 мили
- Research Site 112, Fairfax · на 11 мили
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
Набиране на участнициФаза 2
- Virginia Cancer Specialists, Fairfax · на 11 мили
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Набиране на участнициФаза 1/2
- Virginia Cancer Specialists, Fairfax · на 11 мили
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Набиране на участнициФаза 1/2
- NEXT Virginia, Fairfax · на 11 мили
Проучвания за Рак на белия дроб с недребноклетъчен тип в други градове
- Houston, TX145 проучвания
- New York City, NY120 проучвания
- Nashville, TN97 проучвания
- Boston, MA90 проучвания
- Los Angeles, CA87 проучвания
- St. Louis, MO73 проучвания
- Chicago, IL61 проучвания
- Baltimore, MD60 проучвания
- San Antonio, TX59 проучвания
- Columbus, OH56 проучвания
- Washington, DC55 проучвания
- Seattle, WA53 проучвания
Други проучвания в Arlington
- Метастатичен рак53 проучвания
- Колоректален рак52 проучвания
- Рак (всички видове)48 проучвания
- Рак на гърдата46 проучвания
- Рак на яйчниците46 проучвания
- Рак на белия дроб41 проучвания
- Ендометриален рак39 проучвания
- Рак на панкреаса33 проучвания
- Плоскоклетъчен карцином на главата и шията26 проучвания
- Дребноклетъчен белодробен рак23 проучвания
- Тройно негативен рак на гърдата20 проучвания
- Рак на стомаха20 проучвания
От ClinicalTrials.gov, данни към 5.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.